Standards, estrogenicity

The availability of such a compound would be a major step forward as compared with standard estrogen-based replacement therapy. Such a... 

The MultiCASE system has been used to identify a common 6-A unit biophore on a range of hormonally active chemicals with estrogenic activity that act as endocrine disruptors. This structural feature is a spacer biophore that is thought to be involved in the molecules binding to the estrogen receptor and is found on the standard estrogenic chemical, 17-beta-estradiol (see Combes, 2000). Other examples of molecules possessing this biophore include 4-hydroxytamoxifen, 2-chloro-4-hydroxybiphenyl, 3,4-dihydroxyfluorene, and 2,2-(fcE-4-hydroxyphenyl-1,1,1 -trichloroethane). 

The antimineralocorticoidal activity of drospirenone is considered as a main benefit. It counteracts the salt and water retention effects of ethinylestradiol, the standard estrogen component in oral contraceptives [33]. 

The measurement of ER has become a standard assay in the clinical management of breast cancer. The presence of ERa identifies those breast cancer patients with a lower risk of relapse and better clinical outcome. Receptor status also provides a guideline for those tumors that may be responsive to hormonal intervention. But only about half of ER-positive patients respond to hormonal therapies. Of those who respond initially, most will eventually develop an estrogen unresponsive disease following a period of treatment even though ERa is often still present. Mutant receptors and constitutively active r eceptors as well as hormone-independent activation of the ERa are discussed. The involvement of ER 3 isoforms is under investigation. 

Tamoxifen has been the gold standard for adjuvant endocrine therapy. It has both estrogenic and antiestrogenic properties, depending on the tissue and gene in question. 

All women included in MORE met criteria for osteoporosis defined as a lumbar spine or femoral neck bone mineral density (BMD) T score equal to or less than 2.5 or as the presence of a radiographic vertebral fracture. These women are considered to be at lower risk for breast cancer than women with normal BMD since this parameter could partially reflect a woman s lifetime exposure to estrogens (Zhang et al. 1997). After the start of MORE, NHANES III criteria standardizing total hip BMD measurements became available allowing part of... 

Fig.4 Reconstructed SRM chromatograms obtained from the LC-ESI-MS/MS analysis of a 100 ng mL-1 standard mixture of estrogens (in the NI mode) and progestogens (in the PI mode). Column Purospher STAR RP-18e (125x2 mm, 5 pm, Merck). Mobile phase gradient acetonitrile/water. Flow rate 0.2 mL min-1...

When using purified triolein, most samples are amenable to bioassay after di-alytic enrichment. For example, Microtox bioassay of dialysates of SPMDs shows that the SPMDs made with the purified triolein have lower acute toxicities than dialysates from SPMDs made from unpurified triolein (Johnson, 2001). Finally, examination of the dialysates using the yeast estrogen screen (YES) assay (Routledge and Sumpter, 1996) demonstrated that the purification procedure removes all background estrogenic activity (Lebo et ah, 2004). Use of triolein purified by this process expands the potential applicability of SPMD sample extracts to include numerous bioassay procedures (see Chapter 6) and GC-MS as a standard analysis technique. 

Using a preemptive approach, Lebo et al. (2004) have shown that oleic acid and methyl oleate can be removed from triolein prior to use of the triolein in SPMDs (see Chapters 4 and 5). Dialysates from SPMDs prepared using triolein purified by the Lebo et al. (2004) method exhibited lower acute toxicity (Microtox assay) than SPMDs prepared with unpurified triolein. Also, the YES assay demonstrated that the purification method had removed all background estrogenic activity from SPMD extracts. Eor these reasons, the use of triolein purified by the method of Lebo et al. (2004) is standard for all SPMD studies conducted at CERC, USGS. Also, SPMDs with triolein purified by the Lebo et al. (2004) method are available from the commercial vendor upon request. 

Hypercalcemia Carefully monitor standard hypercalcemia-related metabolic parameters, such as serum levels of calcium, phosphate, and magnesium, as well as serum creatinine. Do not use loop diuretics until the patient is adequately rehydrated use with caution in combination with zoledronic acid in order to avoid hypocalcemia. Use zoledronic acid with caution with other nephrotoxic drugs. Concomitant use with estrogen/hormone replacement therapy (alendronate) Two clinical studies have shown that the degree of suppression of bone turnover (as assessed by mineralizing surface) was significantly greater with the combination than with either component alone. 

Certain tissues of the female reproductive tract, which are subject to the trophic action of hormones, exhibit a high frequency of neoplasia. Cancer of the breast, the second most common form of cancer in American women, and the rarer endometrial cancer in women, are often responsive to treatments with estrogens or progestins. The toxicity of these hormonal treatments compared with standard cancer chemotherapy is low. 

---